GenScript Bio (01548): CARVYKTI generated approximately $555 million in net sales for the fourth quarter.
Kingsway Biotech (01548) released an announcement that, based on the cooperation and licensing agreement signed between Legend and Janssen Biotech, Inc. on December 21, 2017, CARVYKTI is expected to generate approximately $555 million in net sales from trade by the end of the quarter ending December 31, 2025.
GENSCRIPT BIO (01548) announced that, based on the collaboration and licensing agreement established with Legend and Janssen Biotech, Inc. (Johnson & Johnson) on December 21, 2017, CARVYKTI generated approximately 550 million US dollars in net sales in the quarter ending December 31, 2025.
Related Articles

EASY SMART GP (02442): Gong Zhaolong and Du Xiuwen have been appointed as independent non-executive directors.

HAICHANG HLDG (02255) appoints Liu Jiangtao as an executive director and chairman of the board.

Shanghai Longcheer Technology (09611): Hong Kong public offering oversubscribed by 1149.76 times, raising approximately HK$1.52 billion in net proceeds from global offering.
EASY SMART GP (02442): Gong Zhaolong and Du Xiuwen have been appointed as independent non-executive directors.

HAICHANG HLDG (02255) appoints Liu Jiangtao as an executive director and chairman of the board.

Shanghai Longcheer Technology (09611): Hong Kong public offering oversubscribed by 1149.76 times, raising approximately HK$1.52 billion in net proceeds from global offering.

RECOMMEND

Moving Toward “7*24 Hour” Trading! NYSE Seeks Approval For “All‑Weather Blockchain Trading Platform”
21/01/2026

China Internet 2026: Under Pressure From ByteDance, Major Players Launch Full‑Scale Contest For AI Entry Points
21/01/2026

Hong Kong Equity Refinancing Opens Strong In 2026, Raising Over HKD 27 Billion
21/01/2026


